Launching White Paper on
CLL immune-related challenges

Dear members and friends of CLL Advocates Network,

The big day has arrived!

We are delighted to announce that CLL Advocates Network (CLLAN), in partnership with AstraZeneca, has worked with global experts and advocates to develop a White Paper titled “Compromised: Uncovering the immune-related challenges facing people with chronic lymphocytic leukaemia (CLL)” which we are launching today.
 
As we all know, the COVID-19 pandemic has shone a spotlight on the varied immune challenges, in addition to infections, that people with CLL face. This forms a major part of managing day-to-day life with CLL and has long been overlooked in CLL management and care.
 
We are immensely proud of the paper which sets out recommendations needed to achieve improvement in the management of immune challenges for CLL patients.
 
The report highlights the following 4 key recommendations:

1. Creating global clinical guidance for monitoring and managing immunosuppression in people with CLL
2. Ensuring that immunocompromised status is flagged in the patient health records of people with CLL
3. Instigating education and awareness raising activities amongst healthcare professionals, especially primary care physicians
4. Making shared decision-making and personalised approaches commonplace in the management and care of people with CLL

We are incredibly grateful to all the individuals and organisations who have contributed to co-create this one of a kind new White Paper.
 
Please spread the word with your members, colleagues and wider network!

To read the full white paper please click here: 
www.clladvocates.net/whitepaper-CLL-immune-challenges/

EHA 2023
CLLAN/AstraZeneca Patient Advocacy Exchange – Compromised: Uncovering the immune-related challenges facing people with Chronic Lymphocytic Leukaemia 

Hybrid Patient Advocacy Exchange
Dinner will be provided
 

We are inviting you to participate in a European Haematology Association (EHA) Satellite Patient Advocacy Exchange held on:

Saturday 10th June 2023
19:30-21:45 CET,
at NHOW Hotel Frankfurt, Meeting Room – Rupee & Lira
and virtually accessible via Zoom.

The meeting is aimed at Patient Advocacy Group (PAG) representatives and the wider clinical community with a multidisciplinary setting in order to uncover the immune-related challenges facing people with chronic lymphocytic leukaemia and the mental health journey experienced by patients. This non-promotional meeting is organised and funded by AstraZeneca, in partnership with the CLL Advocates Network, and will bring together patient advocates, representatives of Blood Cancer PAGs and Patient and Clinical communities across the globe, with the aim of highlighting the immune challenges faced by CLL patients and sharing information on how patient advocacy can support improvements in care and empower patients. It will be a great opportunity to foster connections between CLL PAGs and the clinical communities globally.

As part of this discussion, we would also like to provide an opportunity for knowledge exchange between PAGs focusing on CLL and PAGs focusing on other blood cancers and the wider clinical communities. This will allow us to gain insights into how the unmet needs of blood cancer patients can be brought to life in different communities.

We are keen to understand your interest in attending this hybrid event. If you are interested in participating, please register by the appropriate link below:

For any patient groups attending in-person here

For patient groups attending virtually here

For the clinical community/external experts attending in person here

Following registration, you will then receive confirmation of your attendance.

We look forward to hearing from you.

Nick York
CLL Advocates Network Steering Committee Chair

Yasmine Hassan
Director, Global Patient Affairs, Oncology
AstraZeneca